Belgium’s Univercells has acquired SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through automated DNA synthesis.
Funding from Gamma supports the development of Univercells’ biomanufacturing platform and bioreactors, with the latter looking to expand into the fast-growing gene therapy segment.